Published in Osteoporos Int on January 13, 2007
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
Cost-effectiveness of injury prevention - a systematic review of municipality based interventions. Cost Eff Resour Alloc (2010) 0.87
Validation and psychometric properties of the commitment to hip protectors (C-HiP) index in long-term care providers of British Columbia, Canada: a cross-sectional survey. BMC Geriatr (2017) 0.75
Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model. Osteoporos Int (2015) 0.75
Systematic implementation of an advance directive program in nursing homes: a randomized controlled trial. JAMA (2000) 3.87
Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA (2003) 3.46
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ (1992) 3.33
Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int (2001) 2.67
Low bone mineral density and risk of fracture in white female nursing home residents. JAMA (2000) 2.15
A cost-benefit analysis of external hip protectors in the nursing home setting. J Am Geriatr Soc (2005) 2.04
Falls and fractures in patients with Alzheimer-type dementia. JAMA (1987) 1.96
Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc (1994) 1.89
The prevalence of osteoporosis in nursing home residents. Osteoporos Int (1999) 1.59
Hip protector compliance: a 13-month study on factors and cost in a long-term care facility. J Am Med Dir Assoc (2003) 1.54
Cost-effectiveness of hip protectors in institutional dwelling elderly. Osteoporos Int (2003) 1.51
Senile dementia of the Alzheimer's type: an important risk factor for serious falls. J Gerontol (1987) 1.38
Acceptance and compliance with external hip protectors: a systematic review of the literature. Osteoporos Int (2002) 1.32
Age and sex as determinants of mortality after hip fracture: 3,895 patients followed for 2.5-18.5 years. J Orthop Trauma (1993) 1.32
Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int (2005) 1.31
Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev (2005) 1.31
The risks of hip fracture in older people from private homes and institutions. Age Ageing (1996) 1.29
The 'NICE' approach to technology assessment: an economics perspective. Health Care Manag Sci (2004) 1.25
Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ (2002) 1.25
Residential status and risk of hip fracture. Age Ageing (1999) 1.22
Hip fractures and Alzheimer's disease in elderly institutionalized Canadians. Ann Epidemiol (2004) 1.22
Nursing home residence and risk of hip fracture. Am J Epidemiol (1996) 1.20
Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff. Osteoporos Int (2003) 1.15
Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol (2006) 1.09
Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. Health Policy (2003) 1.09
Falls in the nursing home: are they preventable? J Am Med Dir Assoc (2004) 1.08
The incidence of hip fractures in independent and institutionalized elderly people. Osteoporos Int (1994) 1.06
Hip fractures. Epidemiology, risk factors, falls, energy absorption, hip protectors, and prevention. Dan Med Bull (1997) 1.00
Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol (2004) 1.00
Increased use of hip protectors in nursing homes: economic analysis of a cluster randomized, controlled trial. J Am Geriatr Soc (2005) 0.94
Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc (1993) 0.94
An economic analysis of external hip protector use in ambulatory nursing facility residents. Age Ageing (2003) 0.93
A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano) (1996) 0.92
Energy-shunting hip padding system attenuates femoral impact force in a simulated fall. J Biomech Eng (1995) 0.90
Cost and effectiveness of hip protectors among the elderly. Int J Technol Assess Health Care (2002) 0.89
Cost-effectiveness of hip protectors in frail institutionalized elderly. Osteoporos Int (2004) 0.88
Cost-effectiveness of fracture prevention treatments in the elderly. Int J Technol Assess Health Care (2004) 0.88
Economic evaluation of interventions for osteoporosis. Osteoporos Int (2002) 0.87
Force attenuation properties of various trochanteric padding materials under typical falling conditions of the elderly. J Bone Miner Res (1994) 0.85
Prevention of hip fracture by external hip protectors: an intervention in 17 nursing homes in two municipalities in Norway. Scand J Public Health (2003) 0.82
An in-service evaluation of hip protector use in residential homes. Age Ageing (2005) 0.80
Are hip protectors cost effective? Injury (2000) 0.78
Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med (1997) 19.00
Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med (1999) 10.94
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
What do we mean by partnership in making decisions about treatment? BMJ (1999) 5.31
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. Proc Natl Acad Sci U S A (1981) 4.77
A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med (1992) 4.60
Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) (2005) 4.41
Controlling health expenditures--the Canadian reality. N Engl J Med (1989) 4.36
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
System for Health Area Resource Planning (SHARP): an application to Ontario medical school enrollment. CMAJ (1994) 4.11
Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol Scand (2003) 3.79
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ (1992) 3.33
Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making (1989) 3.26
Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell (1986) 3.24
Health care contingent valuation studies: a review and classification of the literature. Health Econ (1998) 3.13
The Early External Cephalic Version (ECV) 2 Trial: an international multicentre randomised controlled trial of timing of ECV for breech pregnancies. BJOG (2011) 2.97
The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med (1990) 2.89
Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol (1997) 2.76
Preemptive epidural analgesia and recovery from radical prostatectomy: a randomized controlled trial. JAMA (1998) 2.74
Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum (2006) 2.73
The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev (1998) 2.72
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Universal precautions to prevent HIV transmission to health care workers: an economic analysis. CMAJ (1990) 2.68
Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int (2001) 2.67
Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev (2002) 2.65
Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev (2005) 2.57
The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg (2000) 2.56
Cost-effectiveness ratios: in a league of their own. Health Policy (1994) 2.55
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 2.51
Needle exchange programs: an economic evaluation of a local experience. CMAJ (1997) 2.46
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
N of 1 randomized trials for investigating new drugs. Control Clin Trials (1990) 2.37
Long internal direct repeat in Epstein-Barr virus DNA. J Virol (1982) 2.36
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
RNA encoded by the IR1-U2 region of Epstein-Barr virus DNA in latently infected, growth-transformed cells. J Virol (1983) 2.12
Randomised trial of safety and efficacy of immediate postoperative enteral feeding in patients undergoing gastrointestinal resection. BMJ (1996) 2.06
Agr-independent regulation of fibronectin-binding protein(s) by the regulatory locus sar in Staphylococcus aureus. Mol Microbiol (2000) 2.02
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Abnormalities identified in the knees of asymptomatic volunteers using peripheral magnetic resonance imaging. Osteoarthritis Cartilage (2005) 1.98
Analysis of fluorescence decay curves by means of the Laplace transformation. Biophys J (1975) 1.96
Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol (1996) 1.91
Physician-patient-companion communication and decision-making: a systematic review of triadic medical consultations. Patient Educ Couns (2013) 1.89
Discounting in the economic evaluation of health care interventions. Med Care (1993) 1.89
Comparison of cervical, urethral, and urine specimens for the detection of Chlamydia trachomatis in women. J Infect Dis (1991) 1.87
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The osteoporosis care gap in Canada. BMC Musculoskelet Disord (2004) 1.81
Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum (1993) 1.80
Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J (2008) 1.80
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int (2012) 1.76
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
The biology and chemistry of Epstein-Barr virus. J Infect Dis (1982) 1.74
The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making (1991) 1.73
Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med (2000) 1.71
Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS (1999) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Physician supply in Ontario: further observations on SHARP and the SHARP projections. CMAJ (1995) 1.67
Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol (1995) 1.66
Shared decision making in a publicly funded health care system. Policies exist to reduce the risk of conflict between individual and society. BMJ (1999) 1.65
Estimation of creatinine clearance in elderly persons in long-term care facilities. Am J Med (2001) 1.64
Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev (2003) 1.63
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int (2000) 1.59
Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ (2001) 1.59
How to improve communication between doctors and patients. Learning more about the decision making context is important. BMJ (2000) 1.55
Newborn circumcision: an economic perspective. Can Med Assoc J (1984) 1.54
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making (1996) 1.53
The impact of a gluten-free diet on adults with coeliac disease: results of a national survey. J Hum Nutr Diet (2006) 1.52
Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost (2007) 1.51
Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J Biol Chem (2001) 1.49
erythro-9-[3-(2-Hydroxynonyl)]adenine is an inhibitor of sperm motility that blocks dynein ATPase and protein carboxylmethylase activities. Proc Natl Acad Sci U S A (1981) 1.48
Brca1 required for T cell lineage development but not TCR loci rearrangement. Nat Immunol (2000) 1.48
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Is it 'worthwhile' to continue treating patients with a prolonged stay (>14 days) in the ICU? An economic evaluation. Chest (1998) 1.47
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 1.46
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int (2014) 1.45
Escherichia coli glutaminyl-tRNA synthetase. I. Isolation and DNA sequence of the glnS gene. J Biol Chem (1982) 1.45
Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. Nephrol Dial Transplant (2005) 1.45